-
Blog PostJune 30, 2020Moving beyond amyloid to treat Alzheimer's disease
The repeated clinical trial failures of Alzheimer’s disease therapies based on clearing beta-amyloid have been discouraging, but new research strategies and capabilities are providing renewed hope. -
Blog PostJune 22, 2020How to address secondary findings from genomic testing
Consider this scenario: Jayne is 50 years old and has experienced progressing neurological symptoms over the past two years with no diagnosis. She recently had exome testing which show no genetic variants that explain her symptoms, but identifies a pathogenic variant (mutation) in MSH6. -
Research HighlightJune 12, 2020Using CRISPR technology to control RNA splicing
A research team led by Albert Cheng developed a new method, CASFx, that leverages CRISPR technology to alter messenger RNA splicing and precisely control protein isoform production. -
Blog PostMay 04, 2020Updates in BRCA testing for People of Ashkenazi Jewish Ancestry
The traditional approach to genetic testing for those of Ashkenazi Jewish ancestry is under debate, with some experts calling for testing all Ashkenazi Jewish individuals and others advocating for further research to inform any changes in testing criteria.
-
Search MagazineJune 23, 2020More genetic counselors are needed to realize the potential of precision medicine
The Global Alliance for Genomics and Health predicts that 60 million genomes will be sequenced worldwide by 2025. -
Press ReleaseJune 16, 2020JAX donors contribute $100,000 to new COVID-19 models
A generous gift from Jackson Laboratory (JAX) donors will support the development of new humanized mouse models for beating COVID-19, the infectious disease caused by the novel coronavirus that has infected over 7 million worldwide, killing over 400,000 people. -
Press ReleaseMay 13, 2020National Cancer Institute Renews Jackson Laboratory’s Cancer Center Designation
JAX's Cancer Center designation has been renewed for the 34th year by the National Cancer Institute. -
Blog PostApril 21, 2020CD34+ Hematopoietic Stem Cell Humanized Mice: The Basics
Humanized mouse models serve as an innovative and cost-effective platform to simulate trials, evaluate multiple drugs alone or in combination, and produce predictive data. But, there are a number of questions that frequently arise with this model. Here are some of the more frequent questions and answers to using CD34+ hematopoietic stem cell humanized mice.